1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Daiichi Sankyo said on January 27 that its HER2-targeting antibody drug conjugate (ADC) DS-8201 (trastuzumab deruxtecan) met the primary endpoint of objective response rate (ORR) in a PII study in patients with HER2 overexpressing unresectable or metastatic gastric cancer. The…
To read the full story
Related Article
- Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market
January 8, 2020
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
- Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan
September 10, 2019
BUSINESS
- CureApp’s Alcoholism Therapy App Approved in Japan
February 19, 2025
- Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
- Kyorin Nabs Japan Option for Cyrano’s Post-Viral Smell Loss Drug
February 19, 2025
- COVID Shot Kostaive Lands EU Approval, 1st Nod Outside Japan
February 19, 2025
- Boehringer Files Zongertinib in Japan for HER2 Lung Cancer
February 19, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…